Royalty Pharma $1.3 billion senior notes offering
We advised Royalty Pharma on its SEC-registered investment-grade notes offering, including $600 million in social bonds
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Natera $584.8 million follow-on offering
We advised the underwriters on the SEC-registered stock offering
TScan Therapeutics $100 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Acutus Medical $77 million follow-on offering
We advised Acutus Medical on the SEC-registered stock offering
Sight Sciences $276 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
IVERIC bio $115.2 million stock offering
We advised the underwriters on the SEC-registered equity offering
Kindstar Globalgene Technology HK$2.21 billion IPO
We advised Kindstar Global on its IPO and HKEX listing
IDEAYA Biosciences $92 million follow-on offering
We advised the underwriters on the SEC-registered stock offering
Aligos Therapeutics $83.6 million follow-on offering
We advised the underwriters on the stock offering
Zylox-Tonbridge Medical Technology HK$2.56 billion IPO
We advised Zylox-Tonbridge Medical Technology on its IPO and HKEX listing